The Japanese Journal of Urology
Online ISSN : 1884-7110
Print ISSN : 0021-5287
ANTI-TUMOR EFFECT OF HUMAN RECOMBINANT TUMOR NECROSIS FACTOR ON THE HUMAN RENAL CELL CARCINOMA SERIALLY TRANSPLANTED INTO NUDE MICE
Nobuaki HondaYoshiaki YamadaTadashi MuramatsuHidetoshi FukatsuAkio Segawa
Author information
JOURNAL FREE ACCESS

1988 Volume 79 Issue 10 Pages 1613-1621

Details
Abstract

In order to examine the effect of human recombinant tumor necrosis factor (rHu-TNF) given alone or in combination with human lymphoblastoid interferon (HLBI) against renal cell carcinoma, a sensitivity test was done using xenografts of human renal cell carcinoma serially transplanted in nude mice (AM-RC-3).
The dosages of the drugs used were as follows, rHu-TNF alone was administered daily for 7 days in a dose of 1, 000U, 3, 000U or 10, 000U by either the intra-tumoral or the intravenous route. In the case of combined therapy, rHu-TNF (1, 000U, 3, 000U, or 10, 000U i. t.) and HLBI (107U/kg i. p.) were injected daily for seven days.
The therapeutic effects were evaluated according to the criteria of Battelle Columbus (i. e., relative mean tumor weight (RW) and T/C ratio of RW (TRW/CRW), and the histopathological changes were observed.
Based on the RW, only the group that received intra-tumoral rHu-TNF (10, 000U) showed tumor regression (RW=0.65). In terms of TRW/CRW, marked retardation in tumor growth was seen in the group that received rHu-TNF (10, 000U) alone by intra-tumoral injection (15.3%), or after combination therapy with rHu-TNF (3, 000U or 10, 000U) and HLBI (107U/kg) (27.8% and 39.7%, respectively).
A strong inhibitory effect on tumor growth was recognized in the order of 10, 000U, 3, 000U and 1, 000U after intra-tumoral administration of rHu-TNF alone. This suggests that rHu-TNF exhibits its anti-tumor effect against AM-RC-3 in a dose-dependent manner.
Investigation of the RW and TRW/CRW after intra-tumoral administration and after intravenous injection showed the former route of administration to be more effective than the latter.
As compared to treatment with rHu-TNF alone, combined therapy with HLBI showed a significantly enhanced anti-tumor effect only at a dose of 3, 000U of rHu-TNF.
Histopathologically, remarkable coagulation necrosis of tumor cells accompanied by hemorrhage was demonstrated in the following group: rHu-TNF 3, 000U (i. t.), 10, 000U (i. t.), rHu-TNF 3, 000U (i. t.) plus HLBI 107U/kg and rHu-TNF 10, 000U (i. t.) plus HLBI 107U/kg.

Content from these authors
© Japanese Urological Association
Previous article Next article
feedback
Top